CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Depression is a pervasive mental health condition affecting millions of people worldwide. It can manifest in various ways, from persistent sadness to a lack of energy or interest in daily activities.

“The depression was just a constant,” says Winograd, 54, who lives in Portland, Oregon. Around that time, a doctor friend told him about ketamine for treatment-resistant depression. It wasn ...

GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ...

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...

Ketamine therapy has become known for its effects at combating depression and other mood disorders. There’s a growing body of ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...